

Kaitlyn M Morabito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4717268/publications.pdf>

Version: 2024-02-01

30
papers

6,570
citations

331538

21
h-index

477173

29
g-index

31
all docs

31
docs citations

31
times ranked

11948
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent respiratory syncytial virus infection in a CD14 deficient patient. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	5
2	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	7
3	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021, 54, 769-780.e6.	6.6	37
4	Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans. <i>Journal of Infectious Diseases</i> , 2021, 224, 1550-1555.	1.9	5
5	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. <i>Immunity</i> , 2021, 54, 1869-1882.e6.	6.6	59
6	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1111-1120.	5.2	38
7	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 772864.	2.2	21
8	Vaccination Against Respiratory Syncytial Virus. , 2020, , 665-676.		0
9	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	13.7	1,153
10	An mRNA Vaccine against SARS-CoV-2 â€” Preliminary Report. <i>New England Journal of Medicine</i> , 2020, 383, 1920-1931.	13.9	2,719
11	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020, 6, eaba5068.	4.7	50
12	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
13	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. <i>Frontiers in Immunology</i> , 2020, 11, 842.	2.2	36
14	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30
15	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019, 365, 505-509.	6.0	207
16	Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. <i>Immunity</i> , 2019, 51, 429-442.	6.6	99
17	Epitope-Specific Serological Assays for RSV: Conformation Matters. <i>Vaccines</i> , 2019, 7, 23.	2.1	26
18	DNA vaccination before conception protects Zika virusâ€”exposed pregnant macaques against prolonged viremia and improves fetal outcomes. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	31

#	ARTICLE	IF	CITATIONS
19	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. <i>Lancet, The</i> , 2018, 391, 552-562.	6.3	235
20	Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus. <i>Frontiers in Immunology</i> , 2018, 9, 1861.	2.2	31
21	Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virus-Specific CD8+ T Cell Immunodominance Hierarchy in Neonates. <i>Journal of Immunology</i> , 2017, 198, 394-403.	0.4	20
22	A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. <i>Nature Communications</i> , 2017, 8, 676.	5.8	125
23	Zika Virus Vaccine Development. <i>Journal of Infectious Diseases</i> , 2017, 216, S957-S963.	1.9	38
24	Phenotype and Hierarchy of Two Transgenic T Cell Lines Targeting the Respiratory Syncytial Virus KdM282-90 Epitope Is Transfer Dose-Dependent. <i>PLoS ONE</i> , 2016, 11, e0146781.	1.1	4
25	A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology. <i>PLoS Pathogens</i> , 2016, 12, e1005486.	2.1	18
26	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. <i>Bioconjugate Chemistry</i> , 2016, 27, 2372-2385.	1.8	44
27	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	6.0	348
28	Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses. <i>ACS Biomaterials Science and Engineering</i> , 2016, 2, 2324-2332.	2.6	50
29	Determinants of early life immune responses to RSV infection. <i>Current Opinion in Virology</i> , 2016, 16, 151-157.	2.6	40
30	Quantitative and Qualitative Deficits in Neonatal Lung-Migratory Dendritic Cells Impact the Generation of the CD8+ T Cell Response. <i>PLoS Pathogens</i> , 2014, 10, e1003934.	2.1	78